Aulos Bioscience to Present Updated Phase 1/2 Clinical Trial Results for Novel IL-2 Therapeutic AU-007 in Advanced Solid Tumor Cancers at 2024 ASCO Annual Meeting
2024年4月24日 - 11:23PM
ビジネスワイヤ(英語)
Aulos Bioscience, an immuno-oncology company working to
revolutionize cancer care through the development of potentially
best-in-class IL-2 therapeutics, today announced that updated Phase
1/2 data for AU-007 will be presented at the American Society of
Clinical Oncology (ASCO) 2024 Annual Meeting. AU-007 is a human
IgG1 monoclonal antibody designed using artificial intelligence to
harness the power of interleukin-2 (IL-2) to eradicate solid tumors
in patients with unresectable locally advanced or metastatic
cancers. It is the first AI-designed human monoclonal antibody to
be tested in a clinical trial. The ASCO meeting is being held
online and at McCormick Place in Chicago, Illinois, from May
31–June 4, 2024.
Details of the poster presentation are as follows:
Poster Title: Updated results of a phase 1/2 study of
AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits
CD25 binding, in patients with advanced solid tumors.
Abstract: 2527 Session Type/Title: Poster
Session/Developmental Therapeutics—Immunotherapy Session Date
and Time: Saturday, June 1, 2024, 9:00 a.m.-12:00 p.m. CDT
The poster will be presented in the Exhibit Hall at McCormick
Place. An electronic version will also be available on the ASCO
2024 online meeting platform.
About AU-007 AU-007 is a computationally designed, human
IgG1 monoclonal antibody that is highly selective to the
CD25-binding portion of IL-2. With a mechanism of action unlike any
other IL-2 therapeutic in development, AU-007 leverages IL-2 to
reinforce anti-tumor immune effects. This is achieved by preventing
IL-2, either exogenous or secreted by effector T cells, from
binding to trimeric receptors on regulatory T cells while still
allowing IL-2 to bind and expand effector T cells and NK cells.
This prevents the negative feedback loop caused by other IL-2-based
treatments and biases the immune system toward activation over
suppression. AU-007 also prevents IL-2 from binding to
CD25-containing receptors on eosinophils, as well as vasculature
and pulmonary endothelium, which may significantly reduce the
vascular leak syndrome and pulmonary edema associated with
high-dose IL-2 therapy.
To learn more about the AU-007 Phase 1/2 clinical trial program,
including study locations in the United States and Australia,
please visit ClinicalTrials.gov (identifier: NCT05267626),
www.solidtumorstudy.com (U.S.) and www.solidtumourstudy.com
(Australia).
About Aulos Aulos Bioscience is an immuno-oncology
company working to revolutionize cancer patient care through
best-in-class IL-2 therapeutics that direct patients’ immune
systems toward killing tumor cells. Matching world-class machine
learning from co-founder Biolojic Design with an in-depth
understanding of the immune system, Aulos’ initial clinical
candidate, AU-007, is a computationally designed human antibody
that harnesses the power of IL-2 to induce tumor killing while
limiting the immunosuppression and toxicities typically associated
with this validated pathway. The company was founded by Biolojic
Design and Apple Tree Partners (ATP) and is led by pioneers in the
field of artificial intelligence, antibody development and cancer
immunotherapies. For more information, visit www.aulosbio.com, X
(@AulosBioscience) and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240423874877/en/
Contact: info@aulosbio.com Media inquiries: Mike
Beyer, Sam Brown Inc. / 312-961-2502 / mikebeyer@sambrown.com